{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:05:26Z","timestamp":1780049126363,"version":"3.53.1"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,10,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To assess whether treatment of virilizing congenital adrenal hyperplasia (CAH) with long-acting glucocorticoids is associated with favorable growth outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method.<\/jats:title><jats:p>We examined the long-term growth of 17 boys and 9 girls with CAH treated with dexamethasone (.27 \u00b1 .01 mg\/m2\/day).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>For individuals with comparable bone age (BA) and chronological age (CA) at the onset of dexamethasone therapy, males were 2.8 \u00b1 .8 years (mean \u00b1 standard error of the mean;n = 13) and females were 2.4 \u00b1 1.0 years (n = 6). Males were treated for 7.3 \u00b1 1.1 years (\u0394CA) over which time the change in BA (\u0394BA) was 7.0 \u00b1 1.3 years, and the change in height age (\u0394HA) was 6.9 \u00b1 1.1 years. Females were treated for 6.8 \u00b1 1.3 years, over which time the \u0394BA was 6.5 \u00b1 1.0 years, and the \u0394HA was 6.3 \u00b1 .8 years. During treatment 17 ketosteroid excretion rates were normal for age and 17-hydroxyprogesterone values were 69.6 \u00b1 18 ng\/dL. Testicular enlargement was first detected at 10.7 \u00b1 .8 years and breast tissue at 9.9 \u00b1 1.2 years. Three boys and 1 girl had final heights of 171.8 \u00b1 6 cm and 161 cm, respectively, compared with midparental heights of 176.1 \u00b1 4.1 cm and 160 cm. Predicted adult heights for 6 other boys and 5 girls were 176.8 \u00b1 2.0 cm and 161.4 \u00b1 2.8 cm, respectively, compared with midparental heights of 174.6 \u00b1 1.4 cm and 158.2 \u00b1 2.0 cm. Statural outcomes were less favorable for 7 children started on dexamethasone when BAs were considerably advanced, although height predictions increased during therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>These observations show that children treated with dexamethasone for CAH can achieve normal growth with the convenience of once-a-day dosing in most cases. congenital adrenal hyperplasia, dexamethasone, growth.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.106.4.767","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:50:41Z","timestamp":1092441041000},"page":"767-773","source":"Crossref","is-referenced-by-count":92,"title":["Dexamethasone Treatment of Virilizing Congenital Adrenal Hyperplasia: The Ability to Achieve Normal Growth"],"prefix":"10.1542","volume":"106","author":[{"given":"Scott A.","family":"Rivkees","sequence":"first","affiliation":[{"name":"From the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University Medical School, New Haven, Connecticut; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Pediatric Endocrine Unit, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2000,10,1]]},"reference":[{"key":"2021121009303085300_B1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1172\/JCI101334","article-title":"Adrenal cortical hyperplasia with virilization: diagnosis, course and treatment.","volume":"21","author":"Talbot","year":"1942","journal-title":"J Clin Invest"},{"key":"2021121009303085300_B2"},{"key":"2021121009303085300_B3"},{"key":"2021121009303085300_B4","first-page":"179","article-title":"Congenital adrenal hyperplasia.","volume":"6","author":"New","year":"1997","journal-title":"Curr Ther Endocrinol Metab"},{"key":"2021121009303085300_B5","first-page":"797","article-title":"Congenital adrenal hyperplasia associated with the adrenogenital syndrome: an attempt to correct its disordered pattern.","volume":"29","author":"Bartter","year":"1950","journal-title":"J Clin Invest"},{"key":"2021121009303085300_B6","first-page":"249","article-title":"Suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia.","volume":"86","author":"Wilkins","year":"1950","journal-title":"Bull Johns Hopkins Hosp"},{"key":"2021121009303085300_B7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1749-6632.1985.tb14603.x","article-title":"Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia.","volume":"458","author":"Winterer","year":"1985","journal-title":"Ann N Y Acad Sci"},{"key":"2021121009303085300_B8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000179303","article-title":"Plasma progesterone, 17-hydroxyprogesterone, androstenedione and testosterone in prepubertal, pubertal and adult subjects with congenital virilizing adrenal hyperplasia as indicators of adrenal suppression.","volume":"13","author":"Lee","year":"1980","journal-title":"Horm Res"},{"key":"2021121009303085300_B9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-3476(99)70413-0","article-title":"Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples.","volume":"134","author":"Bode","year":"1999","journal-title":"J Pediatr"},{"key":"2021121009303085300_B10","first-page":"363","article-title":"Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.","volume":"1","author":"David","year":"1994","journal-title":"Arch Pediatr"},{"key":"2021121009303085300_B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3476(74)80277-5","article-title":"Experience with long-term therapy in congenital adrenal hyperplasia.","volume":"85","author":"Brook","year":"1974","journal-title":"J Pediatr"},{"key":"2021121009303085300_B12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/adc.64.11.1554","article-title":"Growth and body proportions in congenital adrenal hyperplasia.","volume":"64","author":"Young","year":"1989","journal-title":"Arch Dis Child"},{"key":"2021121009303085300_B13","first-page":"79","article-title":"Growth and final height in classical and nonclassical 21-hydroxylase deficiency.","volume":"30","author":"New","year":"1988","journal-title":"Acta Paediatr Jpn"},{"key":"2021121009303085300_B14"},{"key":"2021121009303085300_B15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3476(52)80205-7","article-title":"Table for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards.","volume":"40","author":"Bayley","year":"1952","journal-title":"J Pediatr"},{"key":"2021121009303085300_B16"},{"key":"2021121009303085300_B17"},{"key":"2021121009303085300_B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3476(85)80501-1","article-title":"Clinical longitudinal standards for height and height velocity for North American children.","volume":"107","author":"Tanner","year":"1985","journal-title":"J Pediatr"},{"key":"2021121009303085300_B19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1542\/peds.99.4.505","article-title":"Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network.","volume":"99","author":"Herman-Giddens","year":"1997","journal-title":"Pediatrics"},{"key":"2021121009303085300_B20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2265.1987.tb02945.x","article-title":"Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia.","volume":"27","author":"Horrocks","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021121009303085300_B21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2265.1982.tb01627.x","article-title":"A comparison of three glucocorticoid suppressive regimes in adults with congenital adrenal hyperplasia.","volume":"17","author":"Horrocks","year":"1982","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021121009303085300_B22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/adc.65.3.312","article-title":"Dexamethasone treatment for congenital adrenal hyperplasia.","volume":"65","author":"Young","year":"1990","journal-title":"Arch Dis Child"},{"key":"2021121009303085300_B23"},{"key":"2021121009303085300_B24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1440-1754.1993.tb00517.x","article-title":"17-Hydroxyprogesterone rhythms and growth velocity in congenital adrenal hyperplasia.","volume":"29","author":"Pincus","year":"1993","journal-title":"J Paediatr Child Health"},{"key":"2021121009303085300_B25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0026-0495(71)90052-7","article-title":"Single dose dexamethasone in treatment of congenital adrenocortical hyperplasia.","volume":"20","author":"Hayek","year":"1971","journal-title":"Metabolism"},{"key":"2021121009303085300_B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00609429","article-title":"The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia.","volume":"37","author":"Young","year":"1989","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/106\/4\/767\/844737\/767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/106\/4\/767\/844737\/767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T05:06:03Z","timestamp":1705208763000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/106\/4\/767\/65867\/Dexamethasone-Treatment-of-Virilizing-Congenital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10,1]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2000,10,1]]},"published-print":{"date-parts":[[2000,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.106.4.767","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10,1]]}}}